Amolyt Pharma
Created in 2014
Up & running (A)
Existing signals show a regular activitySocial networks
179 9,285 9,285Global tags
Activities
Technologies
Entity types
Location
15 Chem. du Saquin, 69130 Écully, France
Écully
France
Employees
Scale: 11-50
Estimated: 39
SIREN
803919729Engaged catalyst
12
0 0Added in Motherbase
4 years, 1 month ago
Value proposition
Advancing peptides for the treatment of rare endocrine and related diseases
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, Endocrine Disease , and Rare DiseaseOriginal language
Advancing peptides for the treatment of rare endocrine and related diseases
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
AstraZeneca - Research-Based BioPharmaceutical Company
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
https://amolytpharma.com
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 19 Jul 2024 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 15 May 2023 | | |